DPP-4 inhibitors × glycemic control

TrialDiabetes, obesity & metabolism2025

Fotagliptin add-on therapy to metformin in patients with uncontrolled type 2 diabetes: A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.

Nan Yu et al.PubMed ↗Full text ↗Publisher ↗

  • Fotagliptinlooks good hereLower HbA1c level from baseline to week 24.Randomised, small.

What the trial testedrandomised · 2025

Randomised vs placebo

Probably lowered HbA1c level from baseline to week 24

−0.53percentage points−0.68 to −0.39

fotagliptin vs placebo

As reported

difference −0.53 %, 95% CI −0.68 to −0.39 · the paper's word: change in HbA1c level from baseline to week 24

Who was studied, and how

people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

fotagliptin
placebo

Probably lowered HbA1c level from baseline to week 24−0.53

randomised

the abstract, start to end

fotagliptin versus placebo of HbA1c was -0.53% (95% confidence interval [CI]

← favours treatmentfavours comparator →
could be chance
Change in HbA1c level from baseline to week 24fotagliptin vs placebo
−0.53−0.68 to −0.39
DPP-4 inhibitorsGlycemic control

DPP-4 inhibitors × glycemic controlhelps?replicated

unlikelylikely
0.820.82 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 6

2 papers cite it

2025
2026
this papertrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 40302627